Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 3;25(1):192.
doi: 10.1186/s12885-025-13482-9.

Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study

Junjie Fan #  1   2 , Ke Xu  1 , Zhangdong Jiang  1 , Chaosheng Gan  1 , Hao Song  1 , Guoqiang Gao  1 , Guojing Wang  1 , Qiyuan Kang  1 , Liang Luo  3 , Zhuonan Wang  3 , Dalin He  1 , XiaoYi Duan  3 , Kaijie Wu  4
Affiliations

Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study

Junjie Fan et al. BMC Cancer. .

Abstract

Background: Cytoreductive radical prostatectomy (cRP) has emerged as a promising therapeutic approach for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), but the best candidates for cRP are still unknown. This study aims to explore the potential value of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cRP treatment selection among patients with low-volume mHSPC.

Methods: A total of 122 patients with primary low-volume mHSPC who underwent 18F-PSMA-1007 PET/CT followed by systemic therapy alone or plus cRP were included. The whole-body PSMA-derived tumor volume (PSMA-TV) was defined as the total volume of whole-body PSMA-avid tumor lesions, and prostate PSMA-TV was defined as the volume of prostate PSMA-avid tumor lesions. Spearman's correlation was used to analyze the relationships between whole-body PSMA-TV and clinicopathological characteristics. The primary endpoint was progression-free survival (PFS), and Cox regression analyses were performed to explore the independent predictors for PFS.

Results: Among 122 patients, 37 (30.32%) underwent systemic therapy plus cRP. The median and optimal cutoff values of the whole-body PSMA-TV were 71.68 cm3 (41.28-157.41 cm3) and 78.57 cm3, respectively. Whole-body PSMA-TV was positively correlated with prostate-specific antigen (PSA), and patients with nonregional lymph node (NRLN) metastases had a greater whole-body PSMA-TV (P = 0.001). Cox regression analyses revealed that cRP, lower whole-body PSMA-TV and the absence of NRLN metastases were associated with better PFS (all P < 0.05). Subgroup analyses revealed that patients with a low whole-body PSMA or no NRLN metastases had a significant improvement in PFS for cRP versus no cRP (HR: 8.26; 95% CI: 2.72-25.06, P = 0.001; HR: 2.71; 95% CI: 1.25-5.93, P = 0.018). Moreover, among patients with higher prostate PSMA-TV and prostate PSMA-TV/whole-body PSMA-TV, cRP also significantly prolonged PFS compared with those without cRP (HR: 3.49; 95% CI: 1.49-8.18, P = 0.004; HR: 8.54; 95% CI: 2.47-29.50, P = 0.013).

Conclusion: In management of primary low-volume mHSPC, whole-body and prostate PSMA-TV evaluations based on 18F-PSMA-1007 PET/CT could be helpful to identify the most suitable candidates for cRP.

Trial registration: Retrospectively registered.

Keywords: 18F-PSMA-1007 PET/CT; Cytoreductive radical prostatectomy; Low-volume mHSPC; Nonregional lymph node metastases; PSMA-TV.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: All procedures performed in the study and involving human participants were performed in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This retrospective analysis was approved by the Institutional Review Board of the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, P.R. China. Informed consent was obtained from all individual participants included in the study. Consent for publication: Written informed consent was obtained from the patient for publication of this study and accompanying images. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Associations between whole-body PSMA-TV and clinical data. (A) PSA, (B) SUVmax, (C) SUVmean, (D) whole-body TL-PSMA, (E) Gleason score, (F) NRLN metastases
Fig. 2
Fig. 2
Kaplan‒Meier estimates of the impact of cRP in (A) patients with high whole-body PSMA-TV, (B) patients with low whole-body PSMA-TV, (C) patients without NRLN metastases, and (D) patients with NRLN metastases
Fig. 3
Fig. 3
Kaplan‒Meier estimates of the impact of cRP in (A) patients with high prostate PSMA-TV, (B) patients with low prostate PSMA-TV, (C) patients with a high percentage of prostate PSMA-TV/whole-body PSMA-TV, and (D) patients with a low percentage of prostate PSMA-TV/whole-body PSMA-TV
Fig. 4
Fig. 4
18F-PSMA-1007 PET/CT maximum intensity projection images for four representative cases. Patient 1 had a low whole-body PSMA-TV (17.15 cm3), prostate PSMA-TV (2.24 cm3), and prostate PSMA-TV/whole-body PSMA-TV (13.06%). ADT combined with 6 cycles of docetaxel was given, and the PFS was 30 months. Patient 2 had a low whole-body PSMA-TV (31.87 cm3) and a higher percentage of prostate PSMA-TV/whole-body PSMA-TV (88.55%). The PFS was only 12 months after ADT combined with 6 cycles of docetaxel. Patient 3 had a low whole-body PSMA-TV (71.36 cm3) and a high percentage of prostate PSMA-TV/whole-body PSMA-TV (86.19%). Surprisingly, there was no evidence of tumor progression after 34 months of follow-up after treatment with ADT combined with 6 cycles of docetaxel and cRP. Patient 4 had a high whole-body PSMA-TV (123.46 cm3) and NRLN metastases, but the prostate PSMA-TV (62.14 cm3) and the percentage of prostate PSMA-TV/whole-body PSMA-TV (50.33%) were lower. The PFS was only 11 months even after receiving ADT combined with 6 cycles of docetaxel and cRP
See this image and copyright information in PMC

References

    1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate Cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. - DOI - PubMed
    1. Prostate Cancer. [https://www.ncbi.nlm.nih.gov/books/NBK470550/].
    1. Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124(3):401–7. - DOI - PubMed
    1. Matsumura N, Fujita K, Nishimoto M, Minami T, Tahara H, Yoshimura K, Uemura H. Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer. World J Urol. 2023;41(8):2063–8. - DOI - PubMed
    1. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate Cancer: long-term survival analysis of the Randomized Phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080–7. - DOI - PMC - PubMed